| __timestamp | GSK plc | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 3450000000 | 55305000 |
| Thursday, January 1, 2015 | 3560000000 | 77593000 |
| Friday, January 1, 2016 | 3628000000 | 50013000 |
| Sunday, January 1, 2017 | 4476000000 | 58914000 |
| Monday, January 1, 2018 | 3893000000 | 65927000 |
| Tuesday, January 1, 2019 | 4568000000 | 59815000 |
| Wednesday, January 1, 2020 | 5098000000 | 56188000 |
| Friday, January 1, 2021 | 5278000000 | 53012000 |
| Saturday, January 1, 2022 | 5488000000 | 32815000 |
| Sunday, January 1, 2023 | 6223000000 | 27189000 |
| Monday, January 1, 2024 | 25353000 |
Unleashing the power of data
In the ever-evolving landscape of pharmaceuticals, innovation is the lifeblood that drives progress. Over the past decade, GSK plc and Mesoblast Limited have been at the forefront of this innovation race. From 2014 to 2023, GSK plc consistently outpaced Mesoblast Limited in research and development (R&D) investments. GSK's R&D expenses grew by approximately 80%, peaking in 2023, while Mesoblast's investment saw a decline of nearly 50% over the same period.
GSK's commitment to innovation is evident, with its R&D spending reaching its zenith in 2023. In contrast, Mesoblast's investment trajectory has been more volatile, with a notable dip in recent years. This disparity highlights GSK's strategic focus on long-term growth and innovation.
As we look to the future, the question remains: will Mesoblast ramp up its R&D efforts to compete with industry giants like GSK?
Sanofi vs GSK plc: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Vertex Pharmaceuticals Incorporated vs Mesoblast Limited
Who Prioritizes Innovation? R&D Spending Compared for GSK plc and Blueprint Medicines Corporation
Research and Development Investment: GSK plc vs Ionis Pharmaceuticals, Inc.
Comparing Innovation Spending: GSK plc and Supernus Pharmaceuticals, Inc.
R&D Insights: How GSK plc and Novavax, Inc. Allocate Funds
R&D Insights: How Takeda Pharmaceutical Company Limited and Mesoblast Limited Allocate Funds
R&D Insights: How Corcept Therapeutics Incorporated and Mesoblast Limited Allocate Funds
Research and Development: Comparing Key Metrics for Xenon Pharmaceuticals Inc. and Mesoblast Limited
R&D Insights: How Mesoblast Limited and Wave Life Sciences Ltd. Allocate Funds
Research and Development Investment: Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.
Who Prioritizes Innovation? R&D Spending Compared for Mesoblast Limited and Travere Therapeutics, Inc.